Tuberculosis, New England Journal of Medicine, vol.368, issue.8, pp.745-755, 2013. ,
DOI : 10.1056/NEJMra1200894
URL : https://hal.archives-ouvertes.fr/pasteur-00835138
TB vaccines: current status and future perspectives, Immunology and Cell Biology, vol.6, issue.4, pp.279-28614, 2009. ,
DOI : 10.7326/0003-4819-131-1-199907060-00007
The immune response in tuberculosis Annual review of immunology 31, pp.475-52710, 2013. ,
The current state of tuberculosis vaccines, Human Vaccines & Immunotherapeutics, vol.142, issue.10, pp.2142-214610, 2013. ,
DOI : 10.1128/IAI.00592-09
Novel tuberculosis vaccination strategies based on understanding the immune response, Journal of Internal Medicine, vol.2, issue.4 Suppl., pp.337-353, 2010. ,
DOI : 10.4049/jimmunol.181.11.7948
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis, Nature Medicine, vol.13, issue.10, pp.1261-12682420, 2011. ,
DOI : 10.1038/35105052
Current status of TB vaccines, Vaccine, vol.25, issue.19, pp.3742-3751, 2007. ,
DOI : 10.1016/j.vaccine.2007.01.112
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials, Vaccine, vol.31, issue.42, pp.4867-4873051, 2013. ,
DOI : 10.1016/j.vaccine.2013.07.051
Therapy of tuberculosis in mice by DNA vaccination, Nature, vol.400, issue.6741, pp.269-27110, 1999. ,
DOI : 10.1038/22326
Systems approach to tuberculosis vaccine development, Respirology, vol.92, issue.3, pp.412-420, 2013. ,
DOI : 10.1016/S1472-9792(12)70003-3
Tuberculosis vaccine development at a divide Current opinion in pulmonary medicine, pp.294-30010, 2014. ,
infection, Clinical & Experimental Immunology, vol.61, issue.2, pp.235-243, 2009. ,
DOI : 10.4049/jimmunol.178.11.7222
Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants, Infection and immunity, vol.67, pp.4400-4406, 1999. ,
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants, Vaccine, vol.19, issue.17-19, pp.2534-254100553, 2001. ,
DOI : 10.1016/S0264-410X(00)00553-3
Recombinant Mycobacterium bovis BCG Expressing Pertussis Toxin Subunit S1 Induces Protection against an Intracerebral Challenge with Live Bordetella pertussis in Mice, Infection and Immunity, vol.68, issue.9, pp.4877-4883, 2000. ,
DOI : 10.1128/IAI.68.9.4877-4883.2000
Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin, Infection and Immunity, vol.69, issue.2, pp.869-874, 2001. ,
DOI : 10.1128/IAI.69.2.869-874.2001
Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C, Vaccine, vol.22, issue.5-6, pp.740-746017, 2004. ,
DOI : 10.1016/j.vaccine.2003.08.017
Enhancement of Th1 lung immunity induced by recombinant Mycobacterium bovis Bacillus Calmette-Guerin attenuates airway allergic disease American journal of respiratory cell and molecular biology 43, pp.243-25210, 2010. ,
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model Journal of experimental & clinical cancer research: CR 27, pp.10-1186, 2008. ,
The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer, Urologic Oncology: Seminars and Original Investigations, vol.28, issue.5, pp.520-525017, 2008. ,
DOI : 10.1016/j.urolonc.2008.12.017
Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA, Vaccine, vol.21, issue.25-26, pp.3972-398110, 2003. ,
DOI : 10.1016/S0264-410X(03)00295-0
Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guerin Immunity, The Journal of Immunology, vol.177, issue.9, pp.6353-6360, 2006. ,
DOI : 10.4049/jimmunol.177.9.6353
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-?? producing T-cells, Vaccine, vol.27, issue.1, pp.28-37, 2009. ,
DOI : 10.1016/j.vaccine.2008.10.034
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope, AIDS, vol.22, issue.3, pp.339-34810, 2008. ,
DOI : 10.1097/QAD.0b013e3282f3ca57
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin, PLoS ONE, vol.371, issue.9, p.6999, 2009. ,
DOI : 10.1371/journal.pone.0006999.g001
Pulmonary Infection with Hypervirulent Mycobacteria Reveals a Crucial Role for the P2X7 Receptor in Aggressive Forms of Tuberculosis, PLoS Pathogens, vol.541, issue.7, 2014. ,
DOI : 10.1371/journal.ppat.1004188.s003
Evaluation of the overall IFN-?? and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis, Human Vaccines & Immunotherapeutics, vol.174, issue.5, pp.1093-1103, 2013. ,
DOI : 10.1126/science.339.6116.130
Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system, Immunology Letters, vol.88, issue.3, pp.175-18410, 2003. ,
DOI : 10.1016/S0165-2478(03)00043-9
Recent advances towards tuberculosis control: vaccines and biomarkers, Journal of Internal Medicine, vol.393, issue.5, pp.467-48010, 2014. ,
DOI : 10.1111/joim.12212
Vaccine against tuberculosis: what???s new?, S2, pp.10-1186, 2014. ,
DOI : 10.1186/1471-2334-14-S1-S2
Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? The Journal of infectious diseases 199, pp.613-61810, 2009. ,
Transforming growth factor ?? (CiTGF-??) gene expression is induced in the inflammatory reaction of Ciona intestinalis, Developmental & Comparative Immunology, vol.55, pp.102-110, 2015. ,
DOI : 10.1016/j.dci.2015.10.013
TGF-beta-mediated sustained ERK1/2 activity promotes the inhibition of intracellular growth of Mycobacterium avium in epithelioid cells surrogates, PloS one, vol.6, 2011. ,
Protection by novel vaccine candidates, Mycobacterium tuberculosis ??mosR and ??echA7, against challenge with a Mycobacterium tuberculosis Beijing strain, Vaccine, vol.33, issue.42, pp.5633-5639, 2015. ,
DOI : 10.1016/j.vaccine.2015.08.084
Emerging multidrug resistant Mycobacterium tuberculosis strains of the Beijing genotype circulating in Russia express a pattern of biological properties associated with enhanced virulence, Microbes and Infection, vol.12, issue.6, pp.467-475, 2010. ,
DOI : 10.1016/j.micinf.2010.02.008
Pathogenic Mycobacterium bovis strains differ in their ability to modulate the proinflammatory activation phenotype of macrophages, BMC Microbiology, vol.12, issue.1, pp.10-1186, 2012. ,
DOI : 10.1101/pdb.prot5080
A New Recombinant Bacille Calmette???Gu??rin Vaccine Safely Induces Significantly Enhanced Tuberculosis???Specific Immunity in Human Volunteers, The Journal of Infectious Diseases, vol.198, issue.10, pp.1491-150110, 2008. ,
DOI : 10.1086/592450
Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes, Proceedings of the National Academy of Sciences, vol.25, issue.24, pp.5299-5304, 1998. ,
DOI : 10.1126/science.8303277
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis, Nature Medicine, vol.9, issue.5, pp.533-53910, 2003. ,
DOI : 10.1038/nm859
Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV- Unexposed Newborn Infants in South Africa. Clinical and vaccine immunology: CVI 24, doi:10.1128/CVI, pp.439-455, 2017. ,
Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis, Vaccine, vol.33, issue.11, pp.1353-1359058, 2015. ,
DOI : 10.1016/j.vaccine.2015.01.058
Systems approaches to studying the immune response in tuberculosis, Current Opinion in Immunology, vol.25, issue.5, pp.579-587, 2013. ,
DOI : 10.1016/j.coi.2013.08.003
New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development, Vaccine, vol.23, issue.29, pp.3753-3761, 2005. ,
DOI : 10.1016/j.vaccine.2005.03.001
The second Geneva Consensus: Recommendations for novel live TB vaccines, Vaccine, vol.28, issue.11, pp.2259-2270083, 2010. ,
DOI : 10.1016/j.vaccine.2009.12.083
Experimental tuberculosis: Designing a better model to test vaccines against tuberculosis, Tuberculosis, vol.90, issue.2, pp.135-142005, 2010. ,
DOI : 10.1016/j.tube.2010.01.005